Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ALK-Abelló Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Peter Halling

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Peter Halling (47 yo)

1.8yrs

Görev süresi

Mr. Peter Halling is President & Chief Executive Officer of ALK-Abelló A/S from 2023. Mr. Peter Halling served as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experie...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Claus Solje	Executive VP	1.3yrs	DKK 14.86m	Veri yok
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12.4yrs	DKK 6.51m	0.036% DKK 1.8m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.6yrs	DKK 7.18m	Veri yok
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	DKK 350.00k	Veri yok
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	DKK 270.00k	Veri yok
Peter Halling	President & CEO	1.8yrs	Veri yok	Veri yok
Per Plotnikof	VP of Corporate Communications	no data	Veri yok	Veri yok
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.6yrs	Veri yok	Veri yok
Christian Houghton	Head of Product Supply	5.8yrs	Veri yok	Veri yok
Peter Andersen	Senior Vice President of Global Research & Drug Discovery	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 4AJ0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.8yrs	DKK 350.00k	Veri yok
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.6yrs	DKK 270.00k	Veri yok
Jesper Hoiland	Independent Director	1.6yrs	DKK 366.00k	Veri yok
Lene Skole-Sorensen	Vice Chairman of the Board	10.8yrs	DKK 900.00k	Veri yok
Anders Hedegaard	Independent Chairman of the Board	4.6yrs	DKK 1.33m	Veri yok
Lars Holmqvist	Director	9.6yrs	DKK 446.00k	Veri yok
Gitte Aabo	Independent Director	3.6yrs	DKK 523.00k	Veri yok
Alan Main	Independent Director	2.6yrs	DKK 450.00k	Veri yok
Bertil Lindmark	Independent Director	3.6yrs	DKK 500.00k	Veri yok
Nanna Carlson	Employee Representative Director	5.6yrs	DKK 350.00k	Veri yok
Johan Smedsrud	Employee Representative Director	5.6yrs	DKK 350.00k	Veri yok

4.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4AJ0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

ALK-Abelló Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold €1.2m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023)

ALK-Abelló A/S Revises Earnings Guidance for the 2024

Now 20% undervalued after recent price drop

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Now 20% undervalued

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Now 20% undervalued

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

Insider recently sold €1.2m worth of stock

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

Investor sentiment improves as stock rises 18%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Investor sentiment deteriorates as stock falls 17%

Alk-Abelló A/S Announces Executive Changes

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Now 26% undervalued after recent price drop

ALK Announces Management Changes

Full year 2022 earnings released

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 24% undervalued after recent price drop

Alk-Abelló A/S Announces Executive Changes

Now 21% undervalued

First quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

ALK Expects to Submit Registration Application in China for its House Dust Mite (HDM) Sublingual Allergy Immunotherapy (Slit) Tablet Already in 2022

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues in line with analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022

ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022

ALK-Abelló A/S Announces Results from the REACT Study

Third quarter 2021 earnings released

Second quarter 2021 earnings released

ALK-Abelló A/S Revises Earnings Guidance for the Full-Year of 2021

ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. (NasdaqGS:OTIC).

First quarter 2021 earnings released

ALK Provides Earnings Guidance for the Year 2021

Revenue misses expectations

New 90-day high: €364

Full year 2020 earnings released

New 90-day high: €344

ALK-Abelló A/S to Report Q2, 2021 Results on Aug 11, 2021

New 90-day high: €309

Revenue misses expectations

New 90-day high: €306

ALK Announces ITULATEK Sublingual Allergy Immunotherapy (Slit)-Tablet